Stock listing
OTC:AAVXF Abivax SA Stock
US listing (OTC) of Abivax SA · home listing Euronext:ABVX
Follow Abivax SA into a list and get an email when it puts out news.
Share price · OTC:AAVXF
$84.80 USD 0.00 (0.0%)
Close on Nov 6, 2026
- Day range
- $84.80 – $84.80 USDNov 6, 2026
- Market cap
- $7.40B USDAt the close on Nov 6, 2026 · price × 87.27M shares outstanding
- 52-week range
- $71.26 – $139.00 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
- Traded on an average day
- $6,447 USDMedian day 0 shares · 59 days with no trades · last 3 months, Aug 6, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ABVX · Home | €75.50 EUR | -1.40 (-1.8%) | 128,059 | €75.20 | €76.15 | €74.25 | €76.90 | Close on Nov 17, 2026 |
| NASDAQ:ABVX | $82.10 USD | -1.51 (-1.8%) | 1,372,710 | $82.86 | $84.31 | $81.83 | $83.61 | Close on Nov 17, 2026 |
| LSE:0RA9 | €75.15 EUR | -1.75 (-2.3%) | 2,062 | €76.00 | €76.00 | €74.60 | €76.90 | Close on Nov 17, 2026 |
| OTC:AAVXF | $84.80 USD | 0.00 (0.0%) | — | $84.80 | $84.80 | $84.80 | $84.80 | Close on Nov 6, 2026 |
| Frankfurt:2X1 | €77.00 EUR | +1.15 (+1.5%) | 101 | €74.65 | €77.00 | €74.65 | €75.85 | Close on Nov 17, 2026 |
| Frankfurt:2X10 | €74.00 EUR | -3.50 (-4.5%) | 40 | €74.00 | €74.00 | €74.00 | €77.50 | Close on Nov 17, 2026 |
Daily closes
Last 3 months, Aug 6, 2026 – Nov 6, 2026 · OTC:AAVXF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $84.80 | 0.00 | 0.0% | $84.80 | $84.80 | $84.80 | 0 | |
| $84.80 | -54.20 | -39.0% | $84.80 | $84.80 | $84.80 | 100 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 500 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 | |
| $139.00 | 0.00 | 0.0% | $139.00 | $139.00 | $139.00 | 0 |
- Ticker
- OTC:AAVXF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 2, 2026
Abivax to Participate in Upcoming Fall Investor Conferences
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 87 slides
Calls
Replays
Abivax (Euronext:ABVX) Q4 2023 Earnings Call
Mon, Apr 08, 2024 · 8:30 AM ET
Watch Transcript
Latest news
Abivax to Participate in Upcoming Fall Investor Conferences
Nov 2, 2026
Closed $139.00 (0.0%) on Nov 3, 2026
Abivax participera à plusieurs conférences investisseurs cet automne
Nov 2, 2026
Closed $139.00 (0.0%) on Nov 2, 2026
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.26
Oct 23, 2026
Closed $139.00 (0.0%) on Oct 23, 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Sep 30, 2026
Closed $139.00 (0.0%) on Oct 1, 2026
Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
Sep 30, 2026
Closed $139.00 (0.0%) on Sep 30, 2026
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
Sep 25, 2026
Closed $139.00 (0.0%) on Sep 25, 2026
Abivax Presents Business Updates and First Half 2026 Financial Results
Sep 21, 2026
Closed $139.00 (0.0%) on Sep 22, 2026
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Jul 30, 2026
Closed $139.00 (0.0%) on Jul 31, 2026
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
Jul 23, 2026
Closed $139.00 (0.0%) on Jul 24, 2026
Abivax Announces Closing of $920 Million Public Offering
Jul 6, 2026
Closed $80.03 (0.0%) on Jul 7, 2026
Financings
Public offering of american Depositary Shares
Jul 6, 2026
Closed: US$920M raised · Leerink Partners +5
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Van Lanschot Kempen
Use of proceeds: Together with existing cash, to finance operations into the fourth quarter of 2029
Public offering of american Depositary Shares
Jul 2, 2026
Made bigger: about US$920M · US$125 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), Morgan Stanley & Co. LLC (co-lead), Piper Sandler & Co. (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital, Van Lanschot Kempen
Use of proceeds: Potential US commercialization of obefazimod, clinical R&D mainly in ulcerative colitis and Crohn's disease, and general corporate purposes
Announced Jun 30, 2026 · Made bigger Jul 1, 2026 · Made bigger Jul 2, 2026
Public offering of american Depositary Shares
Jul 28, 2025
Closed: US$747.5M raised · US$64 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), Piper Sandler & Co. (co-lead), Guggenheim Securities, LLC (co-lead), LifeSci Capital, BTIG, Van Lanschot Kempen
Use of proceeds: Finance operations into the fourth quarter of 2027, giving 12 months of cash runway after the planned NDA submission for Ulcerative Colitis
Announced Jul 23, 2025 · Update Jul 24, 2025 · Made bigger Jul 25, 2025 · Closed Jul 28, 2025
Decks
Investor Presentation (July 2026)
Investor deck · 87 slides · July 2026
Corporate Update (June 2026)
Corporate update · 56 slides · Jun 29, 2026
Investor Presentation (June 2023)
Investor deck · 35 slides · June 2023
Investor Presentation (May 2023)
Investor deck · 35 slides · May 2023
Abivax SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 49 in all · newest Nov 2, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Apr 8, 2024
- Decks
- 39 decks · latest July 2026
Where Abivax SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ABVX · Home listing | Euronext | France | EUR |
| NASDAQ:ABVX | NASDAQ | United States | USD |
| LS Exchange:A14UQC | LS Exchange | Germany | EUR |
| gettex:2X1 | gettex | Germany | EUR |
| LSE:0RA9 | LSE | United Kingdom | EUR |
| Xetra:2X1 | Xetra | Germany | EUR |
| Tradegate:2X1 | Tradegate | Germany | EUR |
| OTC:AAVXF · This page | OTC | United States | USD |
| Lang & Schwarz:A14UQC | Lang & Schwarz | Germany | EUR |
| Aquis:ABVXP | Aquis | United Kingdom | EUR |
| Frankfurt:2X1 | Frankfurt | Germany | EUR |
| gettex:2X10 | gettex | Germany | EUR |
| BX Swiss:ABVX | BX Swiss | Switzerland | CHF |
| Dusseldorf:2X1 | Dusseldorf | Germany | EUR |
| Lang & Schwarz:A3EWCP | Lang & Schwarz | Germany | EUR |
| Munich:2X1 | Munich | Germany | EUR |
| Hamburg:2X1 | Hamburg | Germany | EUR |
| Aquis:ABVXP | Aquis | United Kingdom | EUR |
| BOATS:ABVX | BOATS | United States | USD |
| Frankfurt:2X10 | Frankfurt | Germany | EUR |
| LS Exchange:A3EWCP | LS Exchange | Germany | EUR |
| Stuttgart:2X1 | Stuttgart | Germany | EUR |
| Turquoise:ABVXP | Turquoise | United Kingdom | EUR |
| VIE:ABVX | Vienna | Austria | EUR |
| Dusseldorf:2X10 | Dusseldorf | Germany | EUR |
| Hamburg:2X10 | Hamburg | Germany | EUR |
| Munich:2X10 | Munich | Germany | EUR |
| Stuttgart:2X10 | Stuttgart | Germany | EUR |
| Tradegate:2X10 | Tradegate | Germany | EUR |
| Hanover:2X1 | Hanover | Germany | EUR |
Log in to ask 6ix AI your own questions about Abivax SA.